The present disclosure relates to parenteral nutrition formulations, including ready-to-use parenteral nutrition formulations which are reconstituted from multi-chamber containers and amino acid formulations. More particularly, the present disclosure is directed to formulations comprising butyrate derivatives, specifically arginine butyrate, for use with adult or pediatric patients. The disclosure further provides for methods of reducing or preventing systemic and local inflammation of patients receiving parenteral nutrition, and methods of maintaining or ameliorating their systemic immunity and local immunity, as well as the patients' gut barrier functions.

A borosilicate glass for a pharmaceutical container having high appearance quality, particularly a small number of air lines, and a glass tube for a pharmaceutical container are provided. The borosilicate glass for a pharmaceutical container contains, in mass %, from 70.0 to 78.0% of SiO.sub.2, from 5.0 to 8.0% of Al.sub.2O.sub.3, from 5.0 to 12.0% of B.sub.2O.sub.3, from 0 to 4.0% of CaO, from 0 to 4.0% of BaO, from 4.0 to 8.0% of Na.sub.2O, from 0 to 5.0% of K.sub.2O and from 0.001 to 1.0% of SnO.sub.2.

A method of providing a remedy is described. The method includes: (i) receiving, from a client device, answers to one or more of sets of questions that are relevant to one or more ailments and/or one or more unique expressions of the ailments; (ii) grading the answers using one or more remedy appropriateness values to produce graded answers, and wherein an remedy appropriateness value quantifies clinical importance of a remedy with respect to a question that is answered; (iii) scoring one or more remedies based on the graded answers to arrive at one or more remedy scores and identifying one or more top remedies that have high remedy scores; (iv) choosing, from a library of frequency files, one or more frequency files that correspond to one or more of the top remedies; and (v) presenting the frequency file as a remedy to the client device.

A liquid dispensing device includes a dispensing end piece and a neck of a reservoir for storing the liquid, the end piece being attached to the neck, which has a tubular internal surface. The end piece has a tubular internal skirt that is mounted in the neck and defines, with the internal surface, at least one annular sealing zone, preventing the liquid from passing between the internal skirt and the neck. The skirt defines, with the internal surface, a separate zone for retaining shavings, which prevents shavings that are formed in the sealing zone while the end piece is being fitted into the neck from getting into the reservoir.

A liquid dispensing device includes a dispensing end piece and a neck of a reservoir for storing the liquid, the end piece being attached to the neck, which has a tubular internal surface. The end piece has a tubular internal skirt that is mounted in the neck and defines, with the internal surface, at least one annular sealing zone, preventing the liquid from passing between the internal skirt and the neck. The skirt defines, with the internal surface, a separate zone for retaining shavings, which prevents shavings that are formed in the sealing zone while the end piece is being fitted into the neck from getting into the reservoir.

The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in the solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof.

The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in the solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof.

A BAK removal device is constructed as a plug of microparticles of a hydrophilic polymeric gel that displays a hydraulic permeability greater than 0.01 Da. The polymer hydrophilic polymeric gel comprises poly(2-hydroxyethyl methacrylate) (pHEMA). The particles are 2 to 100 μm and the plug has a surface area of 30 mm.sup.2 to 2 mm.sup.2 and a length of 2 mm to 25 mm and wherein the microparticles of a hydrophilic polymeric gel has a pore radius of 3 to 60 μm.

A container for storing a medical or pharmaceutical liquid comprising a storage compartment for storing the liquid comprising, an inlet opening for filling the storage compartment and an outlet opening for discharging liquid out of the storage compartment is presented. A hydrophilic membrane layer is arranged within the storage compartment which is gas-tight in a wet condition and which at least covers the outlet opening and contacts the liquid stored within the storage compartment. A dosing assembly and a device for automated release of a medical or pharmaceutical liquid comprising and/or capable of using at least one container are also disclosed.

A container for storing a medical or pharmaceutical liquid comprising a storage compartment for storing the liquid comprising, an inlet opening for filling the storage compartment and an outlet opening for discharging liquid out of the storage compartment is presented. A hydrophilic membrane layer is arranged within the storage compartment which is gas-tight in a wet condition and which at least covers the outlet opening and contacts the liquid stored within the storage compartment. A dosing assembly and a device for automated release of a medical or pharmaceutical liquid comprising and/or capable of using at least one container are also disclosed.